The European Medicines Agency (EMA) is expected to report on Tuesday around 5 p.m. conclusions of the study into potential side effects of the Janssen corona vaccine.

Based on the advice of the EMA, the Netherlands will decide whether or not to use the vaccine.

What's the matter with the Janssen vaccine?

  • In the US, the only country that is already using Janssen, six reports of severe thrombosis plus platelet deficiency have been reported after vaccination.

  • Converted to one report per 1.17 million vaccinees.

  • Whether the disease is really due to the vaccine remains to be seen.

    When millions of people are vaccinated, some can also develop symptoms by chance shortly afterwards.

  • While that is being investigated, the US has shut down vaccinations.

The use of the vaccine was postponed last week by outgoing Minister Hugo de Jonge (Public Health) on the advice of the American parent company of the vaccine, Johnson & Johnson.

The pharmaceutical company advised not to use the vaccines for the time being as a precaution, after reports of serious thrombosis symptoms after vaccination were made in the United States.

In the United States, nearly 7 million people received Janssen's corona vaccine.

Six of them developed blood clots in the brain, along with a small number of platelets, shortly after they were given the vaccine.

In response to these reports, the EMA has investigated whether this is a possibly rare side effect of the vaccine, or whether the women got the complaints by chance.

The vaccine has not yet been used in the Netherlands.

It recently received the first 80,000 doses from the Leiden company, which would be administered to hospital employees, among others.

The Netherlands was expected to be delayed by six weeks at a total stop

When the vaccination with Janssen is completely stopped, the Netherlands is expected to be delayed by six weeks in the vaccination schedule, De Jonge estimated after his decision.

The Netherlands is counting on a total of 11.3 million Janssen vaccines.

The loss of Janssen would then have to be compensated with other vaccines.

An alternative is already available for hospital staff: employees under the age of sixty who provide corona care will be injected with the vaccine from Pfizer / BioNTech if Janssen is absent.

The corona vaccine, which was fourth approved by the EMA on 11 March, has the advantage that only one shot is needed for the vaccine to work optimally.

Thus, with the doses provided, as many people could be fully vaccinated against COVID-19.